Skip to main content
Clinical Trials/NCT06282042
NCT06282042
Recruiting
Not Applicable

Early Transcatheter Mitral Valve Repair After Myocardial Infarction

Fundación para la Investigación Biosanitaria del Principado de Asturias32 sites in 4 countries250 target enrollmentDecember 24, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Mitral Regurgitation
Sponsor
Fundación para la Investigación Biosanitaria del Principado de Asturias
Enrollment
250
Locations
32
Primary Endpoint
All-cause death or Cumulative Heart Failure hospitalizations
Status
Recruiting
Last Updated
6 months ago

Overview

Brief Summary

To explore the impact of early transcatheter edge-to-edge repair of acute functional mitral regurgitation after myocardial infarction on the combined incidence of death and heart-failure associated hospitalisations at one-year follow-up, and quality of life and LV remodelling at two-year follow-up.

Detailed Description

Prospective, multicentre, randomised, open-label, comparative effectiveness clinical trial for the treatment of clinically significant functional mitral regurgitation within 60 days after acute myocardial infarction, who are treated per standard of care and who have been determined by the site's local heart team as inappropriate or too high risk for mitral valve surgery. Eligible subjects will be randomized in a 1:1 ratio to the MitraClip device (intervention group) or to no MitraClip device (Control group).

Registry
clinicaltrials.gov
Start Date
December 24, 2024
End Date
June 16, 2028
Last Updated
6 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fundación para la Investigación Biosanitaria del Principado de Asturias
Responsible Party
Principal Investigator
Principal Investigator

Isaac Pascual Calleja

MD, PhD

Fundación para la Investigación Biosanitaria del Principado de Asturias

Eligibility Criteria

Inclusion Criteria

  • Patients with symptomatic moderate to severe or severe MR after acute MI
  • Age \> 18 years
  • Based on the following classification recently published in "Transcatheter Mitral Edge-to-Edge Repair for Treatment of Acute Mitral Regurgitation" by M. Shuvy et al. (Can J Cardiol. 2023) patients will be included if categorized in Type 2, 3 or 4:

Exclusion Criteria

  • Primary MR (e.g. papillary muscle rupture)
  • Accepted for CABG
  • Presence of cardiogenic shock (AMR type 1)

Outcomes

Primary Outcomes

All-cause death or Cumulative Heart Failure hospitalizations

Time Frame: 12 months

Composite of 1. All-cause death 2. Cumulative Heart Failure hospitalizations

Study Sites (32)

Loading locations...

Similar Trials